Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages

被引:31
作者
Javan, CM
Gooderham, NJ
Edwards, RJ
Davies, DS
Shaunak, S
机构
[1] ROYAL POSTGRAD MED SCH,DEPT INFECT DIS,HUMAN RETROVIRUS GRP,LONDON W12 0NN,ENGLAND
[2] ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12 0NN,ENGLAND
关键词
D O I
10.1089/aid.1997.13.875
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The anti-EW-l activity of sulfated derivatives of dextrin was tested in activated peripheral blood mononuclear cells and in monocyte-derived macrophages using low-passage syncytium-inducing and non-syncytium-inducing primary viral isolates of HIV-1. All four compounds blocked infection in a dose-dependent manner, Dextrin 2-sulfate blocked infection with a 90% inhibitory concentration (IC90) of 69 mu g ml(-1). The IC90 for dextrin 3-sulfate was 50 mu g ml(-1) and for dextrin 6-sulfate was 14 mu g ml(-1). increasing the number of sulfate groups to three per glucan molecule (dextrin 2-, 3-, and 6-sulfate) did not reduce the IC90 further (13 mu g ml(-1)) compared to dextrin 6-sulfate, There was no significant difference in the concentration required to block infection of activated peripheral blood mononuclear cells when compared with monocyte derived macrophages, irrespective of whether low-passage syncytium-inducing or non-syncytium-inducing primary viral isolates of HIV-1 were used, Dextrin a-sulfate and dextrin 6-sulfate also reduced the transmission of HIV-1 in experiments performed using peripheral blood mononuclear cells from HIV-1-positive patients by 6- to 251-fold in a limiting dilution tissue culture infectious dose assay, Sulfated dextrins were not toxic to either primary lymphocytes or macrophages at the concentrations tested, Having previously shown that the cell surface binding of sulfated dextrins is dependent on the position of the negatively charged sulfate groups, we now show that their anti-HIV-1 activity in primary lymphocytes and macrophages is also dependent on the same arrangement, A phase Im clinical trial of dextrin 2-sulfate is now in progress.
引用
收藏
页码:875 / 880
页数:6
相关论文
共 24 条
[1]   INHIBITORY EFFECT OF SELECTED ANTIVIRAL COMPOUNDS ON ARENAVIRUS REPLICATION INVITRO [J].
ANDREI, G ;
DECLERCQ, E .
ANTIVIRAL RESEARCH, 1990, 14 (4-5) :287-300
[2]   SULFATED POLYSACCHARIDES ARE POTENT AND SELECTIVE INHIBITORS OF VARIOUS ENVELOPED VIRUSES, INCLUDING HERPES-SIMPLEX VIRUS, CYTOMEGALO-VIRUS, VESICULAR STOMATITIS-VIRUS, AND HUMAN IMMUNODEFICIENCY VIRUS [J].
BABA, M ;
SNOECK, R ;
PAUWELS, R ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (11) :1742-1745
[3]   HIV REPLICATION IN CD4-NEGATIVE CELL-LINES - EFFECT OF CLONING, CD4 EXPRESSION AND INHIBITION BY DEXTRIN SULFATE [J].
BEDDOWS, S ;
BIENIASZ, P ;
SHAUNAK, S ;
WEBER, J .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (03) :173-177
[4]   HIV-1 VIRION-CELL INTERACTIONS - AN ELECTROSTATIC MODEL OF PATHOGENICITY AND SYNCYTIUM FORMATION [J].
CALLAHAN, L .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (03) :231-233
[5]   DEXTRAN SULFATE BLOCKS ANTIBODY-BINDING TO THE PRINCIPAL NEUTRALIZING DOMAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITHOUT INTERFERING WITH GP120-CD4 INTERACTIONS [J].
CALLAHAN, LN ;
PHELAN, M ;
MALLINSON, M ;
NORCROSS, MA .
JOURNAL OF VIROLOGY, 1991, 65 (03) :1543-1550
[6]   SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING CAPACITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SUBTYPES OTHER THAN B - PHENOTYPIC AND GENOTYPIC CHARACTERISTICS [J].
DEWOLF, F ;
HOGERVORST, E ;
GOUDSMIT, J ;
FENYO, EM ;
RUBSAMENWAIGMANN, H ;
HOLMES, H ;
GALVAOCASTRO, B ;
KARITA, E ;
WASI, C ;
SEMPALA, SDK ;
BAAN, E ;
ZORGDRAGER, F ;
LUKASHOV, V ;
OSMANOV, S ;
KUIKEN, C ;
CORNELISSEN, M ;
BELSEY, EM ;
HEYWARD, W ;
ESPARZA, J ;
VANDEPERRE, P ;
SEMPALA, S ;
TUGUME, B ;
BIRYAHWAHO, B ;
VONBRIESEN, H ;
ESSER, R ;
GREZ, M ;
NEWBERRY, A ;
RANJBAR, S ;
TOMLINSON, P ;
BRADAC, J ;
MCCUTCHAN, F ;
LOUWAGIE, J ;
HEGERICH, P ;
LOPEZGALINDEZ, C ;
OLIVARES, I ;
DOPAZO, J ;
MULLINS, JI ;
DELWART, EL ;
BACHMANN, HM ;
HAHN, BH ;
GAO, F ;
YUE, L ;
SARAGOSTI, S ;
SCHOCHETMAN, G ;
KALISH, M ;
LUO, CC ;
GEORGE, R ;
PAU, CP ;
WEBER, J ;
CHEINGSONGPOPOV, R .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) :1387-1400
[7]   PHENOTYPE-ASSOCIATED SEQUENCE VARIATION IN THE 3RD VARIABLE DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 MOLECULE [J].
FOUCHIER, RAM ;
GROENINK, M ;
KOOTSTRA, NA ;
TERSMETTE, M ;
HUISMAN, HG ;
MIEDEMA, F ;
SCHUITEMAKER, H .
JOURNAL OF VIROLOGY, 1992, 66 (05) :3183-3187
[8]   STANDARDIZATION OF SENSITIVE HUMAN-IMMUNODEFICIENCY-VIRUS COCULTURE PROCEDURES AND ESTABLISHMENT OF A MULTICENTER QUALITY ASSURANCE PROGRAM FOR THE AIDS CLINICAL-TRIALS GROUP [J].
HOLLINGER, FB ;
BREMER, JW ;
MYERS, LE ;
GOLD, JWM ;
MCQUAY, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (07) :1787-1794
[9]  
HOSAYA M, 1991, ANTIMICROB AGENTS CH, V35, P2515
[10]   STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURE ASSAY FOR DETERMINATION OF DRUG SUSCEPTIBILITIES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
JAPOUR, AJ ;
MAYERS, DL ;
JOHNSON, VA ;
KURITZKES, DR ;
BECKETT, LA ;
ARDUINO, JM ;
LANE, J ;
BLACK, RJ ;
REICHELDERFER, PS ;
DAQUILA, RT ;
CRUMPACKER, CS ;
BALFOUR, H ;
ERICE, A ;
COOMBS, R ;
KATZENSTEIN, D ;
LATHEY, J ;
RICHMAN, D ;
MCINTOSH, K ;
RANGAN, S ;
REICHMAN, R ;
SCOTT, W ;
USSERY, M ;
ABRAMS, L ;
MCCUTCHAN, F ;
BURKE, D ;
GARDNER, L ;
ROBERTS, C ;
CHUNG, R ;
HICKS, C ;
SHELLIE, E ;
FOWLER, A ;
MERRITT, L ;
FUJIMURAJUSTICE, M ;
RUIZ, N ;
WAGNER, K ;
GAIL, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1095-1101